Alendronic acid/colecalciferol

Combination drug for osteoporosis

Alendronic acid/colecalciferol is a combination drug used in the treatment of osteoporosis. It combines two active ingredients: alendronic acid, a bisphosphonate that helps to prevent bone loss, and colecalciferol, a form of vitamin D that aids in the absorption of calcium and promotes bone health.

Medical uses

Alendronic acid/colecalciferol is primarily prescribed for the treatment of osteoporosis in postmenopausal women and in men who are at increased risk of fractures. Osteoporosis is a condition characterized by weakened bones and an increased risk of fractures. The combination of alendronic acid and colecalciferol works synergistically to strengthen bones and reduce the likelihood of fractures.

Mechanism of action

Alendronic acid works by inhibiting osteoclast-mediated bone resorption, which is the process by which bone is broken down and its minerals released into the blood. By reducing bone resorption, alendronic acid helps to maintain or increase bone density.

Colecalciferol, also known as vitamin D3, is essential for the absorption of calcium from the gastrointestinal tract. Adequate levels of vitamin D are necessary to ensure that calcium is absorbed efficiently, which is crucial for maintaining healthy bones.

Dosage and administration

Alendronic acid/colecalciferol is typically administered orally, usually as a once-weekly tablet. The tablet should be taken with a full glass of water, at least 30 minutes before any food, beverage, or other medications. Patients are advised to remain upright for at least 30 minutes after taking the medication to reduce the risk of esophageal irritation.

Side effects

Common side effects of alendronic acid/colecalciferol include gastrointestinal issues such as abdominal pain, dyspepsia, and nausea. Some patients may experience musculoskeletal pain. Rare but serious side effects include osteonecrosis of the jaw and atypical femoral fractures.

Contraindications

This medication is contraindicated in patients with abnormalities of the esophagus which delay esophageal emptying, such as stricture or achalasia. It is also contraindicated in patients who cannot stand or sit upright for at least 30 minutes and in those with hypocalcemia.

Related pages

• Osteoporosis
• Bisphosphonate
• Vitamin D
• Calcium